Bellevue Group AG Purchases 13,313 Shares of Pfizer Inc. (NYSE:PFE)

Bellevue Group AG raised its position in Pfizer Inc. (NYSE:PFE) by 139.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 22,868 shares of the biopharmaceutical company’s stock after purchasing an additional 13,313 shares during the period. Bellevue Group AG’s holdings in Pfizer were worth $658,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. GoalVest Advisory LLC increased its stake in Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 811 shares in the last quarter. VisionPoint Advisory Group LLC increased its stake in Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares in the last quarter. Tennessee Valley Asset Management Partners bought a new stake in Pfizer in the fourth quarter valued at approximately $36,000. DiNuzzo Private Wealth Inc. bought a new stake in Pfizer in the fourth quarter valued at approximately $37,000. Finally, Life Planning Partners Inc bought a new stake in Pfizer in the fourth quarter valued at approximately $39,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on PFE shares. Morgan Stanley increased their price objective on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Guggenheim started coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Monday, April 15th. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, BMO Capital Markets reissued an “outperform” rating and set a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Ten investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $35.86.

Pfizer Stock Performance

Shares of PFE stock opened at $27.95 on Tuesday. The stock has a market cap of $158.38 billion, a P/E ratio of -467.76, a P/E/G ratio of 1.12 and a beta of 0.70. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. The company has a fifty day moving average price of $27.51 and a two-hundred day moving average price of $27.83. Pfizer Inc. has a one year low of $25.20 and a one year high of $40.37.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. The firm had revenue of $14.88 billion during the quarter, compared to analysts’ expectations of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The company’s revenue for the quarter was down 19.5% compared to the same quarter last year. During the same quarter last year, the company posted $1.23 earnings per share. As a group, equities analysts predict that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 6.01%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s dividend payout ratio is currently -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.